GCP
GANX icon

GSA Capital Partners’s Gain Therapeutics GANX Stock Holding History

GSA Capital Partners’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Buy
632,131
+319,664
+102% +$589K 0.08% 361
2026
Q1 		$606K Buy
312,467
+291,995
+1,426% +$635K 0.04% 796
2025
Q4 		$66K Buy
+20,472
New +$54.6K 0.01% 1559
2025
Q3 		– Sell
-12,756
Closed -$23K – 1800
2025
Q2 		$23K Buy
+12,756
New +$23.6K ﹤0.01% 1686

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

GSA Capital Partners's GANX Position: Q2 2026 in Review

GSA Capital Partners increased its Gain Therapeutics (GANX) stake by 102% in Q2 2026, buying an estimated $589K and bringing the position to 632,131 shares worth $1.28M. The position accounts for 0.08% of the portfolio, ranked #361.

GSA Capital Partners first reported a position in GANX in Q2 2025 and has held it in 4 quarters since. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • GSA Capital Partners held 632,131 shares of Gain Therapeutics worth $1.28M as of Q2 2026.
  • GSA Capital Partners bought 319,664 Gain Therapeutics shares in Q2 2026, an estimated $589K.
  • Gain Therapeutics made up 0.08% of GSA Capital Partners's portfolio in Q2 2026, its #361 holding.
  • GSA Capital Partners first reported a position in Gain Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.